MedTrace Logo

Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

NCT00371553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2009-07-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the activity of SU011248 in subjects with cisplatin-refractory or multiply relapsed germ cell cancer. It is believed that SU011248 treatment may prove to increase disease response.

Conditions

  • Relapsed or Cisplatin-Refractory Germ Cell Cancer

Interventions

DRUG

SU011248 (Sunitinib)

Sponsors & Collaborators

  • Canadian Urologic Oncology Group

    collaborator OTHER

  • NCIC Testis Group

    collaborator UNKNOWN

  • German Testicular Cancer Study Group

    collaborator OTHER

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Christian K Kollmannsberger, MD · BC Cancer Agency -Vancouver Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371553 on ClinicalTrials.gov